163 related articles for article (PubMed ID: 36398133)
1. Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy.
Argnani L; Broccoli A; Pellegrini C; Fabbri A; Puccini B; Bruna R; Tisi MC; Masia F; Flenghi L; Nizzoli ME; Musso M; Salerno M; Scalzulli PR; Dessi' D; Ferrarini I; Pennese E; Lucchini E; Rossi FG; Minoia C; Gherlinzoni F; Musto P; Patti C; Stefoni V; Zinzani PL
Hemasphere; 2022 Dec; 6(12):e798. PubMed ID: 36398133
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG).
Rattanathammethee T; Norasetthada L; Bunworasate U; Wudhikarn K; Julamanee J; Noiperm P; Lanamtieng T; Phiphitaporn P; Navinpipat M; Kanya P; Jit-Ueakul D; Wongkhantee S; Suwannathen T; Chaloemwong J; Wong P; Makruasi N; Khuhapinant A; Prayongratana K; Niparuck P; Kanitsap N; Suwanban T; Intragumtornchai T
Ann Hematol; 2023 Jul; 102(7):1887-1895. PubMed ID: 37202499
[TBL] [Abstract][Full Text] [Related]
3. A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma.
Terui Y; Rai S; Izutsu K; Yamaguchi M; Takizawa J; Kuroda J; Ishikawa T; Kato K; Suehiro Y; Fukuhara N; Ohmine K; Goto H; Yamamoto K; Kanemura N; Ueda Y; Ishizawa K; Kumagai K; Kawasaki A; Saito T; Hashizume M; Shibayama H
Cancer Sci; 2021 Jul; 112(7):2845-2854. PubMed ID: 33942442
[TBL] [Abstract][Full Text] [Related]
4. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
Diefenbach C; Kahl BS; McMillan A; Briones J; Banerjee L; Cordoba R; Miall F; Burke JM; Hirata J; Jiang Y; Paulson JN; Chang YM; Musick L; Abrisqueta P
Lancet Haematol; 2021 Dec; 8(12):e891-e901. PubMed ID: 34826412
[TBL] [Abstract][Full Text] [Related]
5. Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
Cordoba R; Prawitz T; Westley T; Sharma A; Ambarkhane S; Kapetanakis V; Sabatelli L
Adv Ther; 2022 Jun; 39(6):2668-2687. PubMed ID: 35403948
[TBL] [Abstract][Full Text] [Related]
6. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Sehn LH; Herrera AF; Flowers CR; Kamdar MK; McMillan A; Hertzberg M; Assouline S; Kim TM; Kim WS; Ozcan M; Hirata J; Penuel E; Paulson JN; Cheng J; Ku G; Matasar MJ
J Clin Oncol; 2020 Jan; 38(2):155-165. PubMed ID: 31693429
[TBL] [Abstract][Full Text] [Related]
7. Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey.
Dal MS; Ulu BU; Uzay A; Akay OM; Beşışık S; Yenerel MN; Çelik S; Kaynar L; Yücel OK; Deveci B; Sönmez M; Mehtap Ö; Beköz HS; Sunu C; Salim O; Ulaş T; Kartı S; Altuntaş F; Ferhanoğlu B; Tuğlular TF
Ann Hematol; 2023 Jan; 102(1):133-140. PubMed ID: 36401621
[TBL] [Abstract][Full Text] [Related]
8. [Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant].
Morita Y; Yagi Y; Kanemasa Y; Sasaki Y; Ishimine K; Hayashi Y; Mino M; Ohigashi A; Tamura T; Nakamura S; Okuya T; Shimizuguchi T; Shingai N; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Doki N; Okuyama Y; Ohashi K; Shimoyama T
Rinsho Ketsueki; 2023; 64(7):586-595. PubMed ID: 37544717
[TBL] [Abstract][Full Text] [Related]
9. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
10. [Cohort study of efficacy and safety of polatuzumab vedotin combined with immunochemotherapy in patients with relapse/refractory diffuse large B cell lymphoma].
Wu JQ; Liu YY; Li F; Wu XZJ; Yao ZH; Kong FC; Zhou WL; Tang WY; Teng Y; Feng JF
Zhonghua Yi Xue Za Zhi; 2021 Jul; 101(25):1985-1990. PubMed ID: 34225420
[No Abstract] [Full Text] [Related]
11. RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
Nowakowski GS; Yoon DH; Mondello P; Joffe E; Peters A; Fleury I; Greil R; Ku M; Marks R; Kim K; Zinzani PL; Trotman J; Sabatelli L; Waltl EE; Winderlich M; Sporchia A; Kurukulasuriya NC; Cordoba R; Hess G; Salles G
Ann Hematol; 2023 Jul; 102(7):1773-1787. PubMed ID: 37171597
[TBL] [Abstract][Full Text] [Related]
12. Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.
Vodicka P; Benesova K; Janikova A; Prochazka V; Belada D; Mocikova H; Steinerova K; Duras J; Karban J; Hanackova V; Sykorova A; Obr A; Trneny M
Eur J Haematol; 2022 Aug; 109(2):162-165. PubMed ID: 35502609
[TBL] [Abstract][Full Text] [Related]
13. A retrospective cohort study of polatuzumab vedotin combined with immunochemotherapy in Chinese patients with relapse/refractory diffuse large B cell lymphoma.
Liu Y; Wuxiao Z; Kong F; Feng J; Wu J; Yao Z; Zhou W; Li F
Ann Transl Med; 2022 Oct; 10(19):1070. PubMed ID: 36330404
[TBL] [Abstract][Full Text] [Related]
14. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).
Morschhauser F; Flinn IW; Advani R; Sehn LH; Diefenbach C; Kolibaba K; Press OW; Salles G; Tilly H; Chen AI; Assouline S; Cheson BD; Dreyling M; Hagenbeek A; Zinzani PL; Jones S; Cheng J; Lu D; Penuel E; Hirata J; Wenger M; Chu YW; Sharman J
Lancet Haematol; 2019 May; 6(5):e254-e265. PubMed ID: 30935953
[TBL] [Abstract][Full Text] [Related]
15. Polatuzumab Vedotin: First Global Approval.
Deeks ED
Drugs; 2019 Sep; 79(13):1467-1475. PubMed ID: 31352604
[TBL] [Abstract][Full Text] [Related]
16. Salvage Using Polatuzumab Vedotin Based Therapy in Relapsed Refractory Large B-Cell Lymphomas: Early Experience from a Real-World Middle-Income Setting Using Named-Patient Compassionate Access Program.
Radhakrishnan VS; Pincha R; Raina V; Garg JK; Nag A; Bhave SJ; Achari R; Dey D; Arun I; Lateef Z; Vinarkar SS; Parihar M; Sen S; Mishra DK; Chandy M; Nair R
Indian J Hematol Blood Transfus; 2022 Dec; 39(4):1-5. PubMed ID: 36590655
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on polatuzumab vedotin: new standards for diffuse large B-cell lymphoma?
Ghione P; Salles G
Haematologica; 2024 May; ():. PubMed ID: 38813707
[TBL] [Abstract][Full Text] [Related]
18. Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas.
Dimou M; Papageorgiou SG; Stavroyianni N; Katodritou E; Tsirogianni M; Kalpadakis C; Banti A; Arapaki M; Iliakis T; Bouzani M; Verrou E; Spanoudakis E; Giannouli S; Marinakis T; Mandala E; Mparmparousi D; Sachanas S; Dalekou-Tsolakou M; Hatzimichael E; Vadikolia C; Violaki V; Poziopoulos C; Tsirkinidis P; Chatzileontiadou S; Vervessou E; Ximeri M; Sioni A; Konstantinidou P; Kyrtsonis MC; Siakantaris MP; Angelopoulou MK; Pappa V; Konstantopoulos K; Panayiotidis P; Vassilakopoulos TP
Hematol Oncol; 2021 Aug; 39(3):336-348. PubMed ID: 33583077
[TBL] [Abstract][Full Text] [Related]
19. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
[TBL] [Abstract][Full Text] [Related]
20. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data.
Sehn LH; Hertzberg M; Opat S; Herrera AF; Assouline S; Flowers CR; Kim TM; McMillan A; Ozcan M; Safar V; Salles G; Ku G; Hirata J; Chang YM; Musick L; Matasar MJ
Blood Adv; 2022 Jan; 6(2):533-543. PubMed ID: 34749395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
